Analyst consensus rating
Hemab Therapeutics Analyst Rating: none
Direct answer
Hemab Therapeutics's consensus rating is none.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $62.67.
Forecast evidence checked November 5, 2026.
Get free Hemab Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $44.68
- Average price target
- $62.67
- High price target
- $70.00
- Low price target
- $58.00
- Low target gap
- +29.8%
- Target upside
- +40.3%
- High target gap
- +56.7%
- Target range width
- 26.9%
- Consensus rating
- none
- Analysts
- 6
- Evidence date
- November 5, 2026
- Valid through
- November 12, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Hemab Therapeutics?
Hemab Therapeutics has a verified none consensus. The same dataset has an average price target of $62.67.
How far are Hemab Therapeutics's low and high targets from the recorded price?
The low target implies +29.8%, while the high target implies +56.7%.
How many analysts are included in Hemab Therapeutics's consensus?
The verified consensus includes 6 analysts.
How is Hemab Therapeutics's target upside or downside calculated?
The average target of $62.67 is divided by the recorded price of $44.68, then one is subtracted to produce +40.3%. This does not guarantee a future return.
When was Hemab Therapeutics's analyst forecast verified?
The data was verified on 2026-11-05. The dataset is valid through 2026-11-12.